Share:
SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced the addition of Mary Haak-Frendscho, Ph.D., to the Board of Directors. Dr. Haak-Frendscho currently serves as the president and chief executive officer of Spotlight Therapeutics. Dr. Haak-Frendscho s achievements as a scientist and executive in the biotechnology industry will be invaluable in guiding our growth to a clinical stage company and in expanding the therapeutic breadth of our platforms, said Craig Parker, president and chief executive officer at Surrozen. Our novel approach to selectively harnessing the potential of the Wnt pathway has far-reaching therapeutic potential and I look forward to Dr. Haak-Frendscho s contributions to our mission.